VIVUS (VVUS) Continues To Fatten Up on Back of Qnexa, Up 127% Since FDA News
Tweet
Share
E-mailGet Alerts VVUS Hot Sheet
Join SI Premium – FREE
VIVUS, Inc. (Nasdaq: VVUS) continues higher after last week's FDA panel backing of obesity treatment Qnexa.
Shares of VVUS are up 8 percent today to $23.90 and 127 percent since the news last week.
The PDUFA date for Qnexa is April 17, 2012, when many expect the FDA to formally approve the drug.
Shares of VVUS are up 8 percent today to $23.90 and 127 percent since the news last week.
The PDUFA date for Qnexa is April 17, 2012, when many expect the FDA to formally approve the drug.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Trump: nominate Heidi Overton, MD, PhD, as our next FDA commissioner
- Creative Medical completes enrollment in ADAPT back pain trial
- Blue Star Gold reports phase 2 drilling results at Nutaaq target
Create E-mail Alert Related Categories
FDA, Momentum MoversSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
